Dare Bioscience

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Daré Bioscience reports Q1 progress in women's health innovation

Daré Bioscience showcased progress in Q1 2024 with achievements in product commercialization and pipeline advancements, despite a reported comprehensive loss.
The company's focus on women's health innovation and commitment to driving value for stakeholders position them well for future growth.
While facing financial challenges and competitive pressures, Daré Bioscience has opportunities to capitalize on its strong pipeline and attract investor interest.
Continued momentum in Phase III studies and technology development present avenues for growth and market expansion in the women's health sector.

Dare Bioscience reports strong Q2 earnings, advances women's health therapies

Dare Bioscience delivered a robust Q2 2024 performance marked by cost efficiencies, revenue generation from strategic transactions, and progress in key product developments.
The company's focus on women's health and commitment to advancing therapies position it well for future growth and market leadership in a segment with significant unmet needs.
While facing challenges in market adoption and regulatory interactions, Dare Bioscience has opportunities to drive revenue growth, expand its market presence, and diversify its product portfolio.
Overall, Dare Bioscience's Q2 earnings call reflects a company on a positive trajectory, with a strong financial foundation and a strategic focus on advancing innovative solutions for women's health.

Daré Bioscience reports cost reductions and promising pipeline developments

Daré Bioscience showcased strong financial discipline with notable expense reductions and strategic funding acquisitions, positioning the company for sustainable growth.
Progress in late-stage candidates and FDA interactions signals promising developments in the pipeline, underscoring Daré's commitment to innovation in women's health.
While facing financial challenges and operational hurdles, Daré's focus on disruptive products and leveraging funding opportunities presents avenues for future success.
Overall, Daré Bioscience's Q3 performance reflects a balance of cost management, innovation, and strategic positioning in the healthcare market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conference Call Today at 4:30 p.m. Eastern Time

Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update

SAN DIEGO, April  01, 2020  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it received a Notice of Award of $730,722 in a grant supporting the Ovaprene® postcoital test (PCT) clinical study research from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, a division of the National Institutes of Health (NIH). Having previously received two tranches under the grant, this final tranche brings the total funds under the grant to nearly $2 million. The NIH issued this final notice of award for the PCT project after reviewing data from the completed PCT clinical study and commercialization plans for Ovaprene, an investigational hormone-free, monthly contraceptive.

Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2019 Results - Earnings Call Transcript

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit after a single administration in an investigator-initiated proof of concept study, which is higher than the clinical cure rates of current FDA-approved products

Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis

SAN DIEGO, March  09, 2020  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the presentation of positive findings from a  previously reported  investigational study that used thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in healthy women. The presentation was made at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting 2020, which took place in Orlando, FL, March 5-8, 2020.

Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder

Adaptimmune Therapeutics

Aquestive Therapeutics Inc

BioNTech SE

Nektar Therapeutics

Neon Therapeutics

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.

This Week’s Biggest Biotech Movers

Athenex

Boston Scientific

ConforMIS

Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit (Day 7-14) after a single administration in an investigator-initiated proof of concept study DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit (Day 7-14) after a single administration in an investigator-initiated proof of concept study

Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

Sildenafil Cream, 3.6% has the Potential to Be the First FDA-Approved Product for FSAD Sildenafil Cream, 3.6% has the Potential to Be the First FDA-Approved Product for FSAD

Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation

Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2019 Results - Earnings Call Transcript

Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform

Sildenafil Cream, 3.6% produced statistically significant and clinically meaningful responses compared to placebo cream, further validating the potential for Sildenafil Cream, 3.6% to be an on-demand treatment for FSAD. Sildenafil Cream, 3.6% produced statistically significant and clinically meaningful responses compared to placebo cream, further validating the potential for Sildenafil Cream, 3.6% to be an on-demand treatment for FSAD.

Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference

SAN DIEGO, Oct.  14, 2019  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer, will present at two upcoming investor conferences:

Daré Bioscience to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Oct.  10, 2019  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a poster presentation at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo, which will take place in Philadelphia, Pennsylvania, October 12-16, 2019.

Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo

SAN DIEGO, Oct.  07, 2019  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, Ph.D., its Chief Scientific Officer, will present at the 9th annual Partnership Opportunities in Drug Delivery conference being held October 7-8, 2019 in Boston, MA. Dr. Friend will present an overview of Daré’s segmented intravaginal ring technology and discuss the opportunities to utilize the IVR to target multiple indications.

Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q2 2019 Results - Earnings Call Transcript

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2019 Results - Earnings Call Transcript

Daré Bioscience Inc. (DARE) CEO Sabrina Johnson on Q4 2018 Results - Earnings Call Transcript

Shares of Daré Bioscience Inc.  rocketed 129% on very heavy volume toward a 13-month high in afternoon trade Monday.

Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study

Dare Bioscience Inc, a nanocap biotech company focused on developing therapies for women's health, is enjoying a moment in the spotlight thanks to positive results for its vaginally administered tamoxifen.

News for Dare Bioscience Stock (DARE)